Etex bone substitute gets FDA nod

By Mass High Tech staff

Video Gallery

MHT talks with Tanja Dominko, WPI researcher and CellThera president

MHT talks with Grant McGimpsey, director of the WPI Center for Neuroprosthetics

MHT's Julie Donnelly: Life science startups finding investments

OncoPep licenses cancer vaccine, moves to add $500K to Series A [February 13, 2012]

Oxford Immunotec taps Altieri as CFO [February 13, 2012]

SeraCare selling to Linden for $82M [February 13, 2012]

VBI Vaccines pulls in $2.2M debt round [February 13, 2012]

Biomaterials company Etex Corp. reports the U.S. Food and Drug Administration has approved its bone substitute product, CarriGen.

The company said it will begin selling Carrigen immediately. The product, which is a viscous putty made of nanocrystalline calcium phosphate, is a porous bone graft substitute that sets hard on implantation, filling the defect area, Etex said. The product is intended to be used to fill holes in the bones of the pelvis, extremities and spine. The company said the artificial bone material creates a scaffold-like structure comparatively as strong as natural bone.

Cambridge-based Etex was founded in 1989.

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.